5 results for “partnership”
Acurx will use the MRSA PolC structure to announce a next-wave inhibitor optimization milestone with Leiden researchers.
Antibiotic R&D is constrained by scientific risk and slow iteration cycles; structural biology that clarifies target binding can materially accelerate medicinal chemistry and partnering. MRSA remains a high-profile superbug, making the work both medically and politically salient.
Leiden University Medical Center will deliver a publishable MRSA PolC-inhibitor structure that reshapes Acurx’s next antibiotic development milestones.
Structural clarity can compress drug-discovery timelines and de-risk optimization—especially in antibiotics, where resistance and limited new classes remain a global threat.
Telecom operators will use this deal as a blueprint for AI-led service assurance modernization.
This is a practical enterprise AI story, not a hype cycle headline. It shows where vendors are still finding traction: operational automation, network reliability, and lower manual intervention in telecom back offices.
CSPs will test more AI assurance tools as operators chase faster fault resolution and lower manual workload.
Telecom operators are under pressure to modernize network operations without adding headcount. Partnerships like this show where enterprise AI is actually being sold: workflow automation, fault resolution, and service reliability.
IQVIA will likely use the Medera partnership to deepen its advanced-R&D pitch, while investors watch whether guidance gains convert into earnings.
This is a useful signal on where large clinical-services players are trying to grow: AI, real-world evidence and next-generation therapies. Investors will watch whether the narrative translates into margin expansion.
You're all caught up · last 5 days